GleamWall
中文EN

NSPR InspireMD, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1433607 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY35.8%
TTM net income YoY-7.2%
TTM EPS YoY30.5%
Revenue 3-yr CAGR24.5%
Net income 3-yr CAGR—

Margins

Gross margin12.6%
Operating margin-477.8%
Net margin-469.1%
FCF margin-420.3%
EBITDA margin4,031.1%

Returns

ROE-115.4%
ROA-88.4%
ROIC (approx.)-2,478.3%
Asset turnover0.19x

Leverage & solvency

Liabilities / assets35.2%
Debt / equity0.00x
Current ratio2.99x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-11.3%
Payout ratio—
Capex / revenue11.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.24M$1.77M$3.40M$3.15M$2.52M$1.78M$1.53M$1.95M
Cost of revenue$2.00M$2.54M$2.71M$1.97M$1.66M$1.47M$1.24M$1.48M
Gross profit$240,000-$774,000$687,000$1.18M$864,000$313,000$292,000$469,000
R&D expense$3.27M$4.29M$4.76M$3.48M$3.63M$3.83M$4.06M$3.69M
SG&A expense$3.45M$4.16M$4.72M$4.55M$5.89M$5.33M$4.94M$4.23M
Operating income-$9.95M-$14.45M-$13.98M-$12.08M-$13.05M-$13.02M-$11.46M-$9.37M
Net income-$9.76M-$14.32M-$13.69M-$11.76M-$12.71M-$13.15M-$11.17M-$9.17M
EBITDA-$9.79M-$14.29M-$13.83M$463.58M-$12.92M-$12.91M-$11.36M$270.43M
EPS (basic)-0.12-0.17-0.16—-0.17-0.260.22—
EPS (diluted)-0.12-0.17-0.16—-0.17-0.260.22—
Weighted avg. shares (diluted)85.62M84.66M83.80M—73.47M51.00M49.99M—
Balance sheet
Cash & equivalents$19.25M$15.15M$11.36M$8.94M$63.40M$11.51M$12.38M$18.92M
Short-term investments—$15.27M$30.21M$45.27M—$7.87M$13.70M$15.72M
Receivables$1.90M$1.82M$2.38M$2.17M$1.96M$1.59M$1.58M$1.57M
Inventory$2.99M$2.70M$3.04M$3.40M$3.61M$3.05M$2.82M$2.57M
Current assets$25.65M$36.63M$48.59M$61.47M$70.39M$25.46M$32.14M$40.52M
PP&E, net$3.95M$3.86M$3.65M$3.58M$3.40M$3.10M$2.74M$2.37M
Total assets$33.57M$44.64M$56.47M$69.40M$78.47M$33.34M$38.67M$46.81M
Current liabilities$8.57M$9.65M$9.44M$10.71M$10.82M$9.07M$7.37M$7.68M
Total liabilities$11.82M$13.13M$12.85M$14.20M$14.36M$13.10M$10.33M$10.72M
Shareholders' equity$21.75M$31.51M$43.62M$55.20M$64.11M$20.24M$28.34M$36.09M
Shares outstanding47.12M46.92M46.84M43.53M41.92M32.55M29.75M26.61M
Cash flow statement
Operating cash flow-$10.63M-$10.89M-$12.34M-$9.35M-$8.63M-$8.33M-$8.79M-$6.75M
Capital expenditure$257,000$330,000$194,000$398,000$329,000$576,000$359,000$311,000
Free cash flow-$10.88M-$11.22M-$12.53M-$9.74M-$8.96M-$8.91M-$9.15M-$7.06M
Investing cash flow$14.72M$14.65M$14.78M-$45.13M$7.55M$5.32M$1.70M$8.24M
Financing cash flow———$0$52.93M$2.14M$506,000$1.56M
Depreciation & amortization$168,000$158,000$149,000$475.67M$128,000$107,000$98,000$279.80M
Stock-based compensation$3,000$2.22M$2.10M$2.85M$3.54M$3.21M$2.73M$2.35M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.